Furoxone

(Furazolidone)

ApprovedSmall molecule

UUniversity of Hertfordshire

Furoxone is one of 32 small molecule programs targeting Duodenal Ulcer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Duodenal UlcerActive, not recruiting

Duodenal UlcerApproved

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Duodenal Ulcer

#DrugCompanyPhaseTrials

Aleve

Alnylam Pharmaceuticals

Approved

1 2

Cytotec

Pfizer

Approved

1 3

Bayer Aspirin

Biaxin

Voltaren

Prevacid

10 7

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

1 8

Doryx

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 9

Celebrex

PPhiladelphia Eye Associates

Approved

1 10

Pepcid

KKenvue Brands

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Bismuth Quadruple Therapy

NCT07139366

Clinical

Trials by Indication[1]

Helicobacter Pylori3 trials

Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin

Unknown status·SShandong University·Phase 4·NCT04264663·250 enrolled

Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin

Unknown status·SShandong University·Phase 4·NCT05135182·170 enrolled

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Unknown status·YYanqing Li·Phase 4·NCT03139253·120 enrolled

Helicobacter3 trials

Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·YYongquan Shi·Phase 4·NCT06168084·688 enrolled

Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT04678492·658 enrolled

Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT03609892·658 enrolled

AIN2 trials

Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy

Unknown status·SSir Run Run Shaw Hospital·Phase 4·NCT02894268·300 enrolled

A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication

Completed·SShandong University·Phase 4·NCT03716622·350 enrolled

Helicobacter Pylori Eradication2 trials

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

Not yet recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 1·NCT06777732·672 enrolled

Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04907747·234 enrolled

Helicobacter Pylori Infection2 trials

Empirical Rescue Therapies of Helicobacter Pylori Infection

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01668927·424 enrolled

Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05718609·855 enrolled

3 more indications

Bismuth Quadruple Therapy1 trial

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

Recruiting·YYongquan Shi·Phase 4·NCT07139366·1,248 enrolled

H Pylori Infection1 trial

Furazolidone Quadruple Regimen Eradicate H. Pylori Infection

Completed·LLiaocheng People's Hospital·Phase 1/2·NCT06823791·493 enrolled

Duodenal Ulcer1 trial

The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers

Completed·TThe Third Xiangya Hospital of Central South University·Phase 4·NCT03342456·184 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

FUROXONE

NDA NDA011323

Jan 1, 1982

FUROXONE

NDA NDA011270

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Furazolidone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Furazolidone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Furazolidone. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011323). U.S. Food & Drug Administration.
[5]
SEC EDGAR — University of Hertfordshire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Hertfordshire

Furoxone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Helicobacter Pylori3 trials

Helicobacter3 trials

AIN2 trials

Helicobacter Pylori Eradication2 trials

Helicobacter Pylori Infection2 trials

Bismuth Quadruple Therapy1 trial

H Pylori Infection1 trial

Duodenal Ulcer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News